Vicarious Surgical downgraded to Hold from Buy at Canaccord

Canaccord downgraded Vicarious Surgical to Hold from Buy with a price target of 40c, down from $9. The company reported a “thesis-changing” Q3 report as cost-cutting initiatives coupled with problems integrating its v1.0 system caused it to push timelines 12-18 months out, expecting De Novo submission now in early to mid-2026, the analyst tells investors in a research note. After two cost reductions over the last 12 months and continued timeline delays, the firm is “cognizant of further risk to the timeline going forward.”